お知らせ • Mar 26
Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026 Kuros Biosciences AG, Annual General Meeting, Apr 15, 2026, at 11:00 W. Europe Standard Time. お知らせ • Mar 10
Kuros Biosciences AG Provides Earnings Guidance for the Year 2026-2028 Kuros Biosciences AG provided earnings guidance for the year 2026-2028. For the year, the Group expects at least 35% sales growth.
By 2028, the Group anticipates sales of USD 300 million to USD 330 million. お知らせ • Oct 16
Kuros Biosciences AG Raises earnings Guidance for the Year 2025 Kuros Biosciences AG raised earnings guidance for the year 2025. For the year, Group is raising its sales guidance and now expects growth of at least 70% . お知らせ • Sep 04
Kuros Biosciences Announces Board and Committee Changes Kuros Biosciences announced that Albert Arp has decided to resign from the Board of Directors with immediate effect for personal and professional reasons. Oliver Walker was appointed as Chair of the Audit and Risk Committee. Kimberley Elting was appointed as member of the Audit and Risk Committee and as member and Chair of the Compensation and Nomination Committee. お知らせ • Aug 14
Kuros Biosciences Ag Provides Earnings Guidance for the Year 2025 and by 2027 Kuros Biosciences AG provided earnings guidance for the year 2025 and by 2027. For the year, the company expects robust sales growth of at least 60% in 2025.
Kuros is anticipating sales of USD 220 to 250 million by 2027, reflecting its commitment to long-term value creation through innovation, market share gains, and customer satisfaction. お知らせ • Aug 05
Kuros Biosciences Launches Magnetos MIS Delivery System by Completion of the First U.S. Cases Using the New Magnetos MIS Delivery System Kuros Biosciences announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System - a sterile, prefilled, single-use delivery system engineered for Minimally invasive Surgery in spine procedures. Following FDA 510(k) clearance of the MagnetOs MIS Delivery System in May, these first cases mark a significant milestone in expanding surgeon access to a more streamlined approach for graft delivery. Dr. Daniel Park, orthopedic spine surgeon, performed his first case using the new FDA-cleared system in Southfield, Michigan. MagnetOs MIS builds on the proven science of MagnetOs and its proprietary NeedleGrip submicron surface technology, which harnesses the immune system to stimulate bone growth. It is engineered for precise delivery, surgical efficiency, and predictable fusion outcomes. Compared to delivering MagnetOs in a traditional, funnel-based system, MagnetOs MIS achieved graft placement three times faster, optimizing time in the operating room. The MIS system is supported by robust published clinical evidence for MagnetOs in cases where minimally invasive procedures and surgical site accessibility is crucial. In a retrospective study, MagnetOs achieved a 94.4% fusion rate across 36 levels treated in patients undergoing MIS and open transforaminal lumbar interbody fusions, where the majority of patients had comorbidities such as obesity, smoking, diabetes, or a previous spine surgery. These results build on previously published Level I prospective, randomized, controlled human clinical data demonstrating that MagnetOs achieved nearly twice the fusion rate of autograft in posterolateral fusion (79% vs. 47%). Additionally, and following the recent ANVISA approval of MagnetOs Granules, Kuros also announced that MagnetOs Putty now has been approved by the Brazilian regulatory authority, expanding the company's entry into the South American spine and orthopedic market. お知らせ • Apr 15
Kuros Biosciences Ag Elects Kimberley Elting as A New Member of the Board of Directors Kuros Biosciences AG announced Kimberley Elting was elected as a new member of the Board of Directors. お知らせ • Mar 26
Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025 Kuros Biosciences AG, Annual General Meeting, Apr 15, 2025, at 11:00 W. Europe Standard Time. お知らせ • Oct 10
Kuros Biosciences AG Provides Sales Guidance for the Second Half of 2024 Kuros Biosciences AG provided sales guidance for the second half of 2024. For the remainder of the second half of 2024, Kuros expects a similar seasonal sales pattern as in previous years, corresponding to around 57% to 60% of total annual sales. お知らせ • Apr 17
Kuros Biosciences AG Approves Board of Director and Committee Changes Kuros Biosciences AG at the Annual general meeting approved Board of director and committee changes. Albert Arp and Chris Fair (CEO) were elected as new members of the Board of Directors, Albert Arp was elected as a new member of the Compensation Committee. Scott Bruder did not stand for re-election as member of the board. お知らせ • Mar 08
Kuros Biosciences AG to Report Fiscal Year 2023 Results on Mar 13, 2024 Kuros Biosciences AG announced that they will report fiscal year 2023 results on Mar 13, 2024 お知らせ • Jan 31
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand Kuros Biosciences announced clearance of a 510(k) submission from the U.S. Food and Drug Administration related to its MagnetOs Granules. The Company also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available through Vortek Spine Limited ("Vortek"), a high-tech orthopedic and biologics company specializing in healthcare solutions for surgeons and patients. This further expands the MagnetOs portfolio in terms of application and accessibility. Earlier in January, Kuros announced the FDA clearance of MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, meaning it can now be used without the need for autograft (patient's own bone). The availability of MagnetOs in New Zealand marks a significant milestone for Kuros and the local medical community since patients can now benefit from an advanced bone graft that improves the overall quality of care in orthopedic and spinal procedures. This benefit was further demonstrated with recent level 1 clinical data in which MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population, of which 20% were current smokers. お知らせ • Nov 29
Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal Cages Kuros Biosciences announced that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for use with a bone void filler. With interbody cages being used in almost half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the USA, this news is especially significant for surgeons. MagnetOs Flex Matrix is uniquely well suited to interbody applications. Due to its excellent granule retention, it stays strong yet flexible even when wet - for easy placement either through a funnel or packed directly into any cage, of any size. MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by the FDA for use in posterolateral fusions. Due to its unique fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros' established NeedleGrip surface technology.